These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 19624521)

  • 1. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S; Deifl S; Bohle B
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy.
    Asturias JA; Ibarrola I; Arilla MC; Vidal C; Ferrer A; Gamboa PM; Viñuela JE; Sanz ML; Andreu C; Martínez A
    Clin Exp Allergy; 2009 Jul; 39(7):1088-98. PubMed ID: 19400901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allergen-specific T lymphocytes as targets for specific immunotherapy: striking at the roots of type I allergy.
    Bohle B
    Arch Immunol Ther Exp (Warsz); 2002; 50(4):233-41. PubMed ID: 12371619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural, immunological and functional properties of natural recombinant Pen a 1, the major allergen of Brown Shrimp, Penaeus aztecus.
    Reese G; Schicktanz S; Lauer I; Randow S; Lüttkopf D; Vogel L; Lehrer SB; Vieths S
    Clin Exp Allergy; 2006 Apr; 36(4):517-24. PubMed ID: 16630158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic engineering of pollen allergens for hayfever immunotherapy.
    Bhalla PL
    Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Bugajska-Schretter ; Ball T; Twardosz A; Spitzauer S; Grönlund H; Kraft D
    Biol Chem; 1999; 380(7-8):815-24. PubMed ID: 10494830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant allergens for diagnosis and therapy of allergic disease.
    Chapman MD; Smith AM; Vailes LD; Arruda LK; Dhanaraj V; Pomés A
    J Allergy Clin Immunol; 2000 Sep; 106(3):409-18. PubMed ID: 10984358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine.
    Hellman L
    Eur J Immunol; 1994 Feb; 24(2):415-20. PubMed ID: 8299691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New approaches for allergen-specific immunotherapy].
    Cantillo JF; Puerta L
    Biomedica; 2010; 30(3):440-53. PubMed ID: 21713346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in allergen immunotherapy.
    Nouri-Aria KT
    Iran J Immunol; 2008 Mar; 5(1):1-24. PubMed ID: 18319521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorphism in allergens].
    Lagares A; Puerta L; Caraballo L
    Biomedica; 2002 Mar; 22(1):51-62. PubMed ID: 11957365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6.
    Linhart B; Mothes-Luksch N; Vrtala S; Kneidinger M; Valent P; Valenta R
    Biol Chem; 2008 Jul; 389(7):925-33. PubMed ID: 18627317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunological mechanisms in allergen-specific immunotherapy: impact on future trends in type-1 allergy management].
    Ebner C
    Wien Med Wochenschr; 1999; 149(14-15):438-41. PubMed ID: 10584289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From allergen genes to new forms of allergy diagnosis and treatment.
    Vrtala S
    Allergy; 2008 Mar; 63(3):299-309. PubMed ID: 18269675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.